Combine use of pterostilbene and quercetin for the production of cancer treatment medicaments
View Patent ↗The invention relates to the combined use of pterostilbene and quercetin for the production of cancer treatment medicaments. The in vitro growth of melanoma cells B16-F10 (B16M-F10) is inhibited (56%) by combined exposures of short duration (60 min/day) to PTER (40 μM)+QUER(20 μM) (˜average values of plasma concentrations measured within the first hour following the IV administration of 20 mg of each polyphenol/kg ˜). The combined intravenous administration of PTER+QUER (20 mg/kg× day) to mice inhibits (73%) the metastatic growth of melanoma B16M-F10 in the liver, a common site for metastasis development. The invention demonstrates that the combination of PTER+QUER inhibits the growth of malignant melanoma metastasis and prolongs the survival of the carrier host.
1. A method of treating cancer in a subject which comprises intravenously administering to a subject in need thereof a therapeutically effective amount of a combination of pterostilbene and quercetin (PTER+QUER), including the pharmaceutically acceptable salts thereof.
2. The method as claimed in claim 1 , characterized in that PTER and QUER are administered in combination with a pharmaceutically acceptable excipient.
3. The method as claimed in claim 1 characterized in that the treatment is treatment of a hepatic carcinoma.